Exercise and diet in the management of nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1172-1182

  Mahady, Suzanne E ^a,b   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

diet; exercise; nonalcoholic fatty liver disease; review

Indexed keywords

ALCOHOL; CARBOHYDRATE DERIVATIVE; CHOLINE; CORN SYRUP; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROBIOTIC AGENT; RESVERATROL; SATURATED FATTY ACID; TRANS FATTY ACID;

ADVERSE OUTCOME; ALCOHOL CONSUMPTION; ARTICLE; COFFEE; DIET THERAPY; HUMAN; KINESIOTHERAPY; MACRONUTRIENT; MEDITERRANEAN DIET; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NUT; PATIENT COMPLIANCE; PRIORITY JOURNAL; WEIGHT REDUCTION; LIFESTYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

DIET, MEDITERRANEAN; EXERCISE THERAPY; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84955259240     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.10.032     Document Type: Article

References (137)

1. [1] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346:16 (2002), 1221–1231.
2. [2] Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47:3 (2015), 181–190.
3. [3] Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:6 (2004), 1387–1395.
4. [4] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:1 (2011), 124–131.
5. [5] Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:3 (2013), 593–608.
6. [6] Farrell, G., Wong, V.W.-S., Chitturi, S., NAFLD in Asia — as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
7. [7] Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., Dierkhising, R.A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:4 (2011), 1249–1253.
8. [8] Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685.
9. [9] Mahady, S.E., Webster, A.C., Walker, S., Sanyal, A., George, J., The role of thiazolidinediones in non-alcoholic steatohepatitis — a systematic review and meta analysis. J Hepatol 55:6 (2011), 1383–1390.
10. [10] Ratziu, V., Goodman, Z., Sanyal, A., Current efforts and trends in the treatment of NASH. J Hepatol 62:1 Suppl (2015), S65–S75.
11. [11] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6 (2012), 2005–2023.
12. [12] Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., Marchesini, G., A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53:2 (2010), 372–384.
13. [13] Nseir, W., Hellou, E., Assy, N., Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J Gastroenterol 20:28 (2014), 9338–9344.
14. [14] Del Ben, M., Polimeni, L., Baratta, F., Pastori, D., Loffredo, L., Angelico, F., Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 20:26 (2014), 8341–8350.
15. [15] Fan, J.G., Cao, H.X., Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 28:Suppl 4 (2013), 81–87.
16. [16] Itsiopoulos, C., Brazionis, L., Kaimakamis, M., Cameron, M., Best, J.D., O'Dea, K., et al. Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study. Nutr Metab Cardiovasc Dis 21:9 (2011), 740–747.
17. [17] Esposito, K., Marfella, R., Ciotola, M., Di Palo, C., Giugliano, F., Giugliano, G., et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:12 (2004), 1440–1446.
18. [18] Shah, K., Stufflebam, A., Hilton, T.N., Sinacore, D.R., Klein, S., Villareal, D.T., Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 17:12 (2009), 2162–2168.
19. [19] Estruch, R., Ros, E., Salas-Salvado, J., Covas, M.I., Corella, D., Aros, F., et al. Primary prevention of cardiovascular disease with a Mediterranean diet [Erratum appears in N Engl J Med. 2014 Feb 27;370(9):886]. N Engl J Med 368:14 (2013), 1279–1290.
20. [20] Rees, K., Hartley, L., Flowers, N., Clarke, A., Hooper, L., Thorogood, M., et al. “Mediterranean” dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 8, 2013, CD009825.
21. [21] Nordmann, A.J., Suter-Zimmermann, K., Bucher, H.C., Shai, I., Tuttle, K.R., Estruch, R., et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 124:9 (2011), 841–851.
22. [22] Ryan, M.C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59:1 (2013), 138–143.
23. [23] Simopoulos, A.P., The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56:8 (2002), 365–379.
24. [24] Campbell, A., Price, J., Hiatt, W.R., Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev, 7, 2013, CD003833.
25. [25] Hooper, L., Thompson, R.L., Harrison, R.A., Summerbell, C.D., Moore, H., Worthington, H.V., et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev, 4, 2004, CD003177.
26. [26] James, S., Montgomery, P., Williams, K., Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev, 11, 2011, CD007992.
27. [27] Lawrenson, J.G., Evans, J.R., Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev, 11, 2012, CD010015.
28. [28] Lim, W.S., Gammack, J.K., Van Niekerk, J., Dangour, A.D., Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev, 1, 2006, CD005379.
29. [29] Lev-Tzion, R., Griffiths, A.M., Leder, O., Turner, D., Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, 2, 2014, CD006320.
30. [30] Oliver, C., Watson, H., Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev, 11, 2013, CD002201.
31. [31] Sydenham, E., Dangour, A.D., Lim, W.S., Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev, 6, 2012, CD005379.
32. [32] Hartweg, J., Perera, R., Montori, V., Dinneen, S., Neil, H.A., Farmer, A., Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev, 1, 2008, CD003205.
33. [33] Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [Erratum appears in Lancet 2001 Feb 24;357(9256):642] [Erratum appears in Lancet. 2007 Jan 13;369(9556):106]. Lancet 354:9177 (1999), 447–455.
34. [34] Roncaglioni, M.C., Tombesi, M., Avanzini, F., Barlera, S., Caimi, V., Longoni, P., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors [Erratum appears in N Engl J Med. 2013 May 30;368(22):2146]. N Engl J Med 368:19 (2013), 1800–1808.
35. [35] Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 95:5 (2012), 1003–1012.
36. [36] Nobili, V., Bedogni, G., Alisi, A., Pietrobattista, A., Rise, P., Galli, C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96:4 (2011), 350–353.
37. [37] Scorletti, E., Bhatia, L., McCormick, K.G., Clough, G.F., Nash, K., Hodson, L., et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology 60:4 (2014), 1211–1221.
38. [38] Parker, H.M., Johnson, N.A., Burdon, C.A., Cohn, J.S., O'Connor, H.T., George, J., Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56:4 (2012), 944–951.
39. [39] Sanyal, A.J., Abdelmalek, M.F., Suzuki, A., Cummings, O.W., Chojkier, M., Group E-AS, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147:2 (2014), 377–384.
40. [40] Riccardi, G., Giacco, R., Rivellese, A.A., Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23:4 (2004), 447–456.
41. [41] Schwingshackl, L., Strasser, B., Hoffmann, G., Effects of monounsaturated fatty acids on glycaemic control in patients with abnormal glucose metabolism: a systematic review and meta-analysis. Ann Nutr Metab 58:4 (2011), 290–296.
42. [42] Covas, M.I., Nyyssonen, K., Poulsen, H.E., Kaikkonen, J., Zunft, H.J., Kiesewetter, H., et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial [Summary for patients in Ann Intern Med. 2006 Sep 5;145(5):I53; PMID: 16954356]. Ann Intern Med 145:5 (2006), 333–341.
43. [43] Assy, N., Nassar, F., Nasser, G., Grosovski, M., Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol 15:15 (2009), 1809–1815.
44. [44] Mozaffarian, D., Katan, M.B., Ascherio, A., Stampfer, M.J., Willett, W.C., Trans fatty acids and cardiovascular disease. N Engl J Med 354:15 (2006), 1601–1613 [PubMed PMID: 16611951. English].
45. [45] Stender, S., Dyerberg, J., Astrup, A., High levels of industrially produced trans fat in popular fast foods. N Engl J Med 354:15 (2006), 1650–1652.
46. [46] Allison, D.B., Egan, S.K., Barraj, L.M., Caughman, C., Infante, M., Heimbach, J.T., Estimated intakes of trans fatty and other fatty acids in the US population. J Am Diet Assoc 99:2 (1999), 166–174.
47. [47] Ibrahim, A., Natrajan, S., Ghafoorunissa, R., Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism 54:2 (2005), 240–246.
48. [48] Tetri, L.H., Basaranoglu, M., Brunt, E.M., Yerian, L.M., Neuschwander-Tetri, B.A., Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:5 (2008), G987–G995.
49. [49] Neuschwander-Tetri, B.A., Ford, D.A., Acharya, S., Gilkey, G., Basaranoglu, M., Tetri, L.H., et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 47:10 (2012), 941–950.
50. [50] Dowman, J.K., Hopkins, L.J., Reynolds, G.M., Nikolaou, N., Armstrong, M.J., Shaw, J.C., et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 184:5 (2014), 1550–1561.
51. [51] Obara, N., Fukushima, K., Ueno, Y., Wakui, Y., Kimura, O., Tamai, K., et al. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. J Hepatol 53:2 (2010), 326–334.
52. [52] Savard, C., Tartaglione, E.V., Kuver, R., Haigh, W.G., Farrell, G.C., Subramanian, S., et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 57:1 (2013), 81–92.
53. [53] Mozaffarian, D., Micha, R., Wallace, S., Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 7(3), 2010, e1000252.
54. [54] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:12 (2008), 1461–1465.
55. [55] Hoekstra, M., Li, Z., Kruijt, J.K., Van Eck, M., Van Berkel, T.J., Kuiper, J., The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol 52:2 (2010), 244–251.
56. [56] Hao, L., Ito, K., Huang, K.H., Sae-tan, S., Lambert, J.D., Ross, A.C., Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells. Metabolism 63:10 (2014), 1352–1362.
57. [57] Tappy, L., Le, K.A., Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 90:1 (2010), 23–46.
58. [58] Teff, K.L., Elliott, S.S., Tschop, M., Kieffer, T.J., Rader, D., Heiman, M., et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 89:6 (2004), 2963–2972.
59. [59] Elliott, S.S., Keim, N.L., Stern, J.S., Teff, K., Havel, P.J., Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 76:5 (2002), 911–922.
60. [60] Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:6 (2010), 1961–1971.
61. [61] Lecoultre, V., Egli, L., Carrel, G., Theytaz, F., Kreis, R., Schneiter, P., et al. Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans. Obesity (Silver Spring) 21:4 (2013), 782–785.
62. [62] Maersk, M., Belza, A., Stodkilde-Jorgensen, H., Ringgaard, S., Chabanova, E., Thomsen, H., et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 95:2 (2012), 283–289.
63. [63] de Wit, N.J., Afman, L.A., Mensink, M., Muller, M., Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 57:6 (2012), 1370–1373.
64. [64] Johnston, R.D., Stephenson, M.C., Crossland, H., Cordon, S.M., Palcidi, E., Cox, E.F., et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 145:5 (2013), 1016–1025.
65. [65] Pham, M., Lemberg, D.A., Day, A.S., Probiotics: sorting the evidence from the myths. Med J Aust 188:5 (2008), 304–308.
66. [66] Schnabl, B., Brenner, D.A., Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146:6 (2014), 1513–1524.
67. [67] Duseja, A., Chawla, Y.K., Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 18:1 (2014), 59–71.
68. [68] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:6 (2009), 1877–1887.
69. [69] Wong, V.W., Won, G.L., Chim, A.M., Chu, W.C., Yeung, D.K., Li, K.C., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12:2 (2013), 256–262.
70. [70] Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., Hekmatdoost, A., Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99:3 (2014), 535–542.
71. [71] Ma, Y.Y., Li, L., Yu, C.H., Shen, Z., Chen, L.H., Li, Y.M., Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 19:40 (2013), 6911–6918.
72. [72] Torres, D.M., Harrison, S.A., Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology 144:4 (2013), 670–672.
73. [73] Chen, S., Teoh, N.C., Chitturi, S., Farrell, G.C., Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?. J Gastroenterol Hepatol 29:3 (2014), 435–441.
74. [74] Zelber-Sagi, S., Salomone, F., Webb, M., Lotan, R., Yeshua, H., Halpern, Z., et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 165:3 (2015), 428–436.
75. [75] Modi, A.A., Feld, J.J., Park, Y., Kleiner, D.E., Everhart, J.E., Liang, T.J., et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51:1 (2010), 201–209.
76. [76] Molloy, J.W., Calcagno, C.J., Williams, C.D., Jones, F.J., Torres, D.M., Harrison, S.A., Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55:2 (2012), 429–436.
77. [77] Johnson, S., Koh, W.P., Wang, R., Govindarajan, S., Yu, M.C., Yuan, J.M., Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 22:3 (2011), 503–510.
78. [78] Han, J.M., Jo, A.N., Lee, S.M., Bae, H.S., Jun, D.W., Cho, Y.K., et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 29:6 (2014), 1265–1272.
79. [79] Ros, E., Nuts and novel biomarkers of cardiovascular disease. Am J Clin Nutr 89:5 (2009), 1649S–1656S.
80. [80] Tapsell, L.C., Gillen, L.J., Patch, C.S., Batterham, M., Owen, A., Bare, M., et al. Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care 27:12 (2004), 2777–2783.
81. [81] Moriya, A., Iwasaki, Y., Ohguchi, S., Kayashima, E., Mitsumune, T., Taniguchi, H., et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33:3 (2011), 378–388.
82. [82] Ekstedt, M., Franzen, L.E., Holmqvist, M., Bendtsen, P., Mathiesen, U.L., Bodemar, G., et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 44:3 (2009), 366–374.
83. [83] Nascimbeni, F., Pais, R., Bellentani, S., Day, C.P., Ratziu, V., Loria, P., et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 59:4 (2013), 859–871.
84. [84] Gentile, C.L., Nivala, A.M., Gonzales, J.C., Pfaffenbach, K.T., Wang, D., Wei, Y., et al. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol. 301:6 (2011), R1710–R1722.
85. [85] Bortolotti, M., Maiolo, E., Corazza, M., Van Dijke, E., Schneiter, P., Boss, A., et al. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. Clin Nutr 30:4 (2011), 494–498.
86. [86] Corbin, K.D., Zeisel, S.H., Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 28:2 (2012), 159–165.
87. [87] Brasnyo, P., Molnar, G.A., Mohas, M., Marko, L., Laczy, B., Cseh, J., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106:3 (2011), 383–389.
88. [88] Reimer, R.A., Grover, G.J., Koetzner, L., Gahler, R.J., Lyon, M.R., Wood, S., The soluble fiber complex PolyGlycopleX lowers serum triglycerides and reduces hepatic steatosis in high-sucrose-fed rats. Nutr Res 31:4 (2011), 296–301.
89. [89] Parnell, J.A., Raman, M., Rioux, K.P., Reimer, R.A., The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 32:5 (2012), 701–711.
90. [90] Brockman, D.A., Chen, X., Gallaher, D.D., High-viscosity dietary fibers reduce adiposity and decrease hepatic steatosis in rats fed a high-fat diet. J Nutr 144:9 (2014), 1415–1422.
91. [91] Fock, K.M., Khoo, J., Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 28:Suppl. 4 (2013), 59–63.
92. [92] Johansson, K., Sundstrom, J., Marcus, C., Hemmingsson, E., Neovius, M., Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes (Lond) 38:2 (2014), 279–284.
93. [93] Foster, G.D., Wyatt, H.R., Hill, J.O., McGuckin, B.G., Brill, C., Mohammed, B.S., et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:21 (2003), 2082–2090.
94. [94] Brinkworth, G.D., Buckley, J.D., Noakes, M., Clifton, P.M., Wilson, C.J., Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. Arch Intern Med 169:20 (2009), 1873–1880.
95. [95] Halton, T.L., Hu, F.B., The effects of high protein diets on thermogenesis, satiety and weight loss: a critical review. J Am Coll Nutr 23:5 (2004), 373–385.
96. [96] Santesso, N., Akl, E.A., Bianchi, M., Mente, A., Mustafa, R., Heels-Ansdell, D., et al. Effects of higher- versus lower-protein diets on health outcomes: a systematic review and meta-analysis. Eur J Clin Nutr 66:7 (2012), 780–788.
97. [97] Garber, C.E., Blissmer, B., Deschenes, M.R., Franklin, B.A., Lamonte, M.J., Lee, I.M., et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 43:7 (2011), 1334–1359.
98. [98] Healy, G.N., Wijndaele, K., Dunstan, D.W., Shaw, J.E., Salmon, J., Zimmet, P.Z., et al. Objectively measured sedentary time, physical activity, and metabolic risk: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Diabetes Care 31:2 (2008), 369–371.
99. [99] Helmrich, S.P., Ragland, D.R., Leung, R.W., Paffenbarger, R.S., Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325:3 (1991), 147–152.
100. [100] Park, Y.W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M.R., Heymsfield, S.B., The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 163:4 (2003), 427–436.
101. [101] Price, J.K., Srivastava, R., Bai, C., Diao, G., Gerber, L.H., Younossi, Z.M., Comparison of activity level among patients with chronic liver disease. Disabil Rehabil 35:11 (2013), 907–912.
102. [102] Perseghin, G., Lattuada, G., De Cobelli, F., Ragogna, F., Ntali, G., Esposito, A., et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 30:3 (2007), 683–688.
103. [103] Krasnoff, J.B., Painter, P.L., Wallace, J.P., Bass, N.M., Merriman, R.B., Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 47:4 (2008), 1158–1166.
104. [104] Kistler, K.D., Brunt, E.M., Clark, J.M., Diehl, A.M., Sallis, J.F., Schwimmer, J.B., et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 106:3 (2011), 460–468.
105. [105] St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J., Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 50:1 (2009), 68–76.
106. [106] Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 58:4 (2013), 1287–1295.
107. [107] Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:1 (1997), 103–107.
108. [108] Keating, S.E., Hackett, D.A., George, J., Johnson, N.A., Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 57:1 (2012), 157–166.
109. [109] Helmerhorst, H.J., Wijndaele, K., Brage, S., Wareham, N.J., Ekelund, U., Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes 58:8 (2009), 1776–1779.
110. [110] Petersen, C.B., Nielsen, A.J., Bauman, A., Tolstrup, J.S., Joint association of physical activity in leisure and total sitting time with metabolic syndrome amongst 15,235 Danish adults: a cross-sectional study. Prev Med 69 (2014), 5–7.
111. [111] Wagner, A., Dallongeville, J., Haas, B., Ruidavets, J.B., Amouyel, P., Ferrieres, J., et al. Sedentary behaviour, physical activity and dietary patterns are independently associated with the metabolic syndrome. Diabetes Metab 38:5 (2012), 428–435.
112. [112] Wijndaele, K., Duvigneaud, N., Matton, L., Duquet, W., Delecluse, C., Thomis, M., et al. Sedentary behaviour, physical activity and a continuous metabolic syndrome risk score in adults. Eur J Clin Nutr 63:3 (2009), 421–429.
113. [113] Willey, K.A., Singh, M.A., Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights. Diabetes Care 26:5 (2003), 1580–1588.
114. [114] Burgomaster, K.A., Howarth, K.R., Phillips, S.M., Rakobowchuk, M., Macdonald, M.J., McGee, S.L., et al. Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans. J Physiol Lond 586:1 (2008), 151–160.
115. [115] Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I., Goldiner, I., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48:6 (2008), 1791–1798.
116. [116] Johnson, N.A., George, J., Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52:1 (2010), 370–381.
117. [117] Jakovljevic, D.G., Hallsworth, K., Zalewski, P., Thoma, C., Klawe, J.J., Day, C.P., et al. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. Clin Sci (Colch) 125:3 (2013), 143–149.
118. [118] Ferriolli, E., Pessanha, F.P., Marchesi, J.C., Diabetes and exercise in the elderly. Med Sport Sci 60 (2014), 122–129.
119. [119] Peng, L., Wang, J., Li, F., Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev, 6, 2011, CD003619.
120. [120] Johnson, N.A., Sachinwalla, T., Walton, D.W., Smith, K., Armstrong, A., Thompson, M.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50:4 (2009), 1105–1112.
121. [121] Promrat, K., Kleiner, D.E., Niemeier, H.M., Jackvony, E., Kearns, M., Wands, J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:1 (2010), 121–129.
122. [122] Vilar, E., Martínez, Y., Calzadilla, L., Torres, A., Gra, B., Gonzalez, L., et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:2 (2015), 367–378.
123. [123] Harrison, S.A., Fecht, W., Brunt, E.M., Neuschwander-Tetri, B.A., Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49:1 (2009), 80–86.
124. [124] Andersen, T., Gluud, C., Franzmann, M.B., Christoffersen, P., Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12:2 (1991), 224–229.
125. [125] Rozental, P., Biava, C., Spencer, H., Zimmerman, H.J., Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 12:2 (1967), 198–208 [PubMed PMID: 6016689. English].
126. [126] Younossi, Z.M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91:6 (2012), 319–327.
127. [127] Liu, C.J., Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 27:10 (2012), 1555–1560.
128. [128] Fabricatore, A.N., Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference?. J Am Diet Assoc 107:1 (2007), 92–99.
129. [129] Butler, A.C., Chapman, J.E., Forman, E.M., Beck, A.T., The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 26:1 (2006), 17–31.
130. [130] Corbalan, M.D., Morales, E.M., Canteras, M., Espallardo, A., Hernandez, T., Garaulet, M., Effectiveness of cognitive-behavioral therapy based on the Mediterranean diet for the treatment of obesity. Nutrition 25:7-8 (2009), 861–869.
131. [131] Dalle Grave, R., Calugi, S., Molinari, E., Petroni, M.L., Bondi, M., Compare, A., et al. Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res 13:11 (2005), 1961–1969.
132. [132] Newton, J.L., Jones, D.E., Henderson, E., Kane, L., Wilton, K., Burt, A.D., et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 57:6 (2008), 807–813.
133. [133] Frith, J., Day, C.P., Robinson, L., Elliott, C., Jones, D.E., Newton, J.L., Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 52:1 (2010), 112–116.
134. [134] Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:6 (2002), 393–403.
135. [135] Shaw, K., O'Rourke, P., Del Mar, C., Kenardy, J., Psychological interventions for overweight or obesity. Cochrane Database Syst Rev, 2, 2005, CD003818.
136. [136] Moscatiello, S., Di Luzio, R., Bugianesi, E., Suppini, A., Hickman, I.J., Di Domizio, S., et al. Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study. Obesity 19:4 (2011), 763–770.
137. [137] Bellentani, S., Dalle Grave, R., Suppini, A., Marchesini, G., Fatty Liver Italian Network, Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 47:2 (2008), 746–754.